There was a very large controversy last December at ASH in Orlando. Two studies which followed long-term Revlimid users found they had an 8% risk of developing a form of Acute Myeloid Leukemia (AML).
Revlimid is manufactured by Celgene Pharmaceuticals, a publicly traded company. This news caused Celgene’s stock to crash and rumors to explode in and around the meetings.
I ran a series of stories about the news as it hit the main stream press. Here are links to two of those articles:
As is often the case, it looks like this news wasn’t really news at all. As a matter of fact, several prominent myeloma specialists stepped-up and went on the record saying they did not think there was a secondary cancer risk to using Revlimid.
One was Dr. Rajkumar of Mayo Clinic. My friend and fellow myeloma patient, Nick van Dyk, went one step further. Nick, who is a patient at the Myeloma Institute (UAMS) in Little Rock, Arkansas, spoke with the facility’s director, Dr. Barlogie, about the study results last week.
Nick e-mailed me a few days ago and shared that “Dr. Barlogie is very firmly of the opinion that Revlimid does not cause secondary cancer. He said they have (UAMS) observed hundreds of patients for more than five years and they have never seen a single case of secondary cancer from it.”
Great news, Nick! Thanks for the “scoop!”
Feel good and keep smiling! Pat